Investor Relations

Celgene Corporation and its subsidiaries (collectively "we", "our" or "us") is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID^®, VIDAZA^®, THALOMID^® (inclusive of Thalidomide Celgene^® and Thalidomide Pharmion^®), ABRAXANE^®, whi... More >>

Date Title   06/17/13 Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Treatment indicated for patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS) with an isolated chromosomal abnormality called deletion 5q BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 17, 2013-- Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with tra...  06/14/13 Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease Statistically Significant Results in Primary and All Secondary Endpoints Achieved in Rare Orphan Disease No Approved Therapies in US or Europe for Rare Chronic Inflammatory Disorder BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 14, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet’s disease (BD) ...  06/13/13 Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR Signs and symptoms in patients with psoriatic arthritis significantly Improved with apremilast treatment in PALACE 3 Patients treated with apremilast demonstrated improvement across key secondary endpoints in PALACE 3 Safety and tolerability profile in PALACE 3 was comparable to previously-reported PALACE studies ABSTRACT #SAT0299; OP0104; SAT0280 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 13, 2013-- Celgene Inte...  06/12/13 Celgene Announces Additional $3.0 Billion Share Repurchase Program SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 12, 2013-- Celgene Corporation (NASDAQ: CELG) announced today that its Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company’s common stock. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by management and in accordance with applicable requirements of the Securities and Exchange Commission. Year-t...

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit.